Compare Logitech International SA (LOGI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Viatris Inc — how do they compare? Logitech International SA trades at $102.33 (market cap $14.96B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| LOGI | VTRS | |
|---|---|---|
Market Cap | $14.96B | $18.69B |
Sector | Technology | Health |
52-Week High | $126.69 | $17.86 |
52-Week Low | $85.84 | $9.49 |
Enterprise Value | $13.30B | $30.80B |
Dividend Yield | 1.64% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.92, down 2.81% amid technical bearish signals and supply chain concerns. The stock shows strong fundamentals with three consecutive quarterly earnings beats, robust 35.29% ROE, and 16.28% net margins. Recent Q1 2027 results exceeded expectations with $1.85 EPS versus $1.26 expected, though a semiconductor supplier shutdown creates near-term uncertainty.
Outlook remains mixed with 26% upside to consensus $109.75 target but tempered by supply risks. Investment case hinges on Logitech's premium product demand and margin expansion potential, balanced against Q3 2027 supply constraints and divided analyst sentiment (26% Buy, 47% Hold, 26% Sell).
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
